Table 1 Baseline characteristics of patients treated with pamidronate iv or oral bisphosphonates
Variables | Â | Oral Bisphosphonates n = 31 | Pamidronate n = 30 | p value |
|---|---|---|---|---|
Duration of treatment (years) | mean (range) | 4.2 (4.9) | 4.3 (4.8) | 0.914 |
Age (years) | mean (SD) | 62 (13.9) | 67 (9.6) | 0.132 |
Gender (female) | n (%) | 24 (77) | 24 (80) | 0.527 |
Age at menopause (years) | mean (SD) | 48 (4.6) | 46 (5.3) | 0.178 |
BMI (kg/m2) | mean (SD) | 24 (4.7) | 25 (4.5) | 0.636 |
Number of patients with at least 1 clinical fracture | n (%) | 9 (29) | 5 (17) | 0.251 |
Familial fractures | n (%) | 12 (36) | 11 (37) | 0.516 |
Dietary calcium intake (mg/day) | mean (SD) | 925 (366) | 838 (241) | 0.293 |
Calcium supplementation daily dose (mg) | n (%) | 12 | 9 | 0.678 |
| Â | mean (SD) | 541 (144) | 610 (334) | 0.531 |
Treatment with prednisone daily dose (mg) | n (%) | 6 (18) | 5 (17) | 0.835 |
| Â | mean (SD) | 10 (4.2) | 11.5 (6) | 0.638 |
T score spine | mean (SD) | -2.39 (1.55) | -2.58 (0.89) | 0.562 |
T score hip | mean (SD) | -1.85 (1.13) | -1.79 (1.03) | 0.816 |
Serum 25(OH) D levels (nmol/l) | mean (SD) | 70 (31) | 62 (29) | 0.313 |
Serum calcium levels (mmol/l) | mean (SD) | 2.38 (0.1) | 2.39 (0.1) | 0.678 |
Serum albumin levels (g/l) | mean (SD) | 41 (9) | 39 (4) | 0.356 |